Effect of administration route on the biodistribution and shedding of replication-deficient HAdV-5: A qualitative modelling approach

Current Gene Therapy

Volumn 10, Issue 2, 2010, Pages 107-127

  Tiesjema, Birgitte ^a   Hermsen, Harm P H ^a   Van Eijkeren, Jan C H ^a   Brandon, Esther F A ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Adenovirus; Distribution; Excretion; Gene therapy; Qualitative model; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR;

BLOOD BRAIN BARRIER; DRUG DISTRIBUTION; GENE THERAPY; HUMAN; HUMAN ADENOVIRUS; NONHUMAN; QUALITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SPERM; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS SHEDDING;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; DNA, RECOMBINANT; DRUG ADMINISTRATION ROUTES; GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; VIRUS REPLICATION; VIRUS SHEDDING;

ADENOVIRIDAE;

EID: 77950959733     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310791111038     Document Type: Review

References (96)

1. Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991; 88: 1651-1655.
2. Verhaagh S, de Jong E, Goudsmit J, et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J Gen Virol 2006; 87: 255-265. (Pubitemid 43169250)
3. Kostense S, Koudstaal W, Sprangers M, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18: 1213-1216. (Pubitemid 38738525)
4. Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-8271. (Pubitemid 36871454)
5. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11: 351-357. (Pubitemid 38380817)
6. Ginsberg H.S. L-BUPG. Adenovirus as a model of disease. Russel W, Ed. Molecular basis of virus disease. New York: Cambridge University press 1987; pp. 245-258.
7. Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009; 108: 778-790.
8. Leon RP, Hedlund T, Meech SJ, et al. Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci USA 1998; 95: 13159-13164.
9. Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415-419. (Pubitemid 28048853)
10. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356. (Pubitemid 27157315)
11. Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: many means to many ends. Adv Drug Deliv Rev 2007; 59: 810-821.
12. Goldman MJ, Wilson JM. Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol 1995; 69: 5951-5958.
13. Huang S, Endo RI, Nemerow GR. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995; 69: 2257-2263.
14. Fechner H, Haack A, Wang H, et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 6: 1520-1535.
15. Nagai M, Yaoita E, Yoshida Y, et al. Coxsackievirus and adenovirus receptor, a tight junction membrane protein, is expressed in glomerular podocytes in the kidney. Lab Invest 2003; 83: 901-911. (Pubitemid 36723699)
16. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001; 61: 6592-6600. (Pubitemid 32783269)
17. Lyons M, Onion D, Green NK, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 2006; 14: 118-128. (Pubitemid 44191831)
18. Nicklin SA, Wu E, Nemerow GR, Baker AH. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005; 12: 384-393. (Pubitemid 41150124)
19. Kalyuzhniy O , Di Paolo NC, Silvestry M, et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A. 2008; 105: 5483-5488. (Pubitemid 351753889)
20. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409. (Pubitemid 351200513)
21. Waddington SN, Parker AL, Havenga MJ, et al. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 2007; 81: 9568-9571.
22. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007; 7: 189-204. (Pubitemid 46902201)
23. Sakurai F, Kawabata K, Mizuguchi H. Adenovirus vectors composed of subgroup B adenoviruses. Curr Gene Ther 2007; 7 : 229-238. (Pubitemid 47232955)
24. Vivčs RR, Lortat-Jacob H, Fender P. Heparan sulphate proteoglycans and viral vectors : ally or foe? Curr Gene Ther 2006; 6: 35-44.
25. Segura MM, Alba R, Bosch A, Chillón M. Advances in helper-dependent adenoviral vector research. Curr Gene Ther 2008; 8: 222-235.
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Considerations. General Principles to Address Virus and Vector Shedding June 2009; Available at http://www.ich.org/LOB/media/MEDIA5521.pdf.
27. Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9: 910-921. (Pubitemid 47543258)
28. Moullier P, Snyder RO. International efforts for recombinant adeno-associated viral vector reference standards. Mol Ther 2008; 16: 1185-1188. (Pubitemid 351866048)
29. Gonin P, Gaillard C. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther 2004; 11 (Suppl 1): S98-S108. (Pubitemid 39359454)
30. Brandon E, Tiesjema B, van Eijkeren J, Hermsen H. Effect of administration route on biodistribution and shedding of replication-deficient viral vectors used in gene therapy: a literature study. RIVM report no 320001001. 2008.
31. Johnson M, Huyn S, Burton J, Sato M, Wu L. Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 2006; 17: 1262-1269.
32. Xu XX, Shui X, Chen ZH, Shan CQ, Hou YN, Cheng YG. Development and application of a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus. Mol Biotechnol 2009; 43: 130-137.
33. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletion increases the safety, efficacy and persistence of adenovirusmediated gene transfer in vivo. Gene Ther 1997; 4: 309-316.
34. Stone D, Liu Y, Li ZY, Tuve S, Strauss R, Lieber A. Comparison of adenoviruses from species B, C, e, and f after intravenous delivery. Mol Ther 2007; 15: 2146-2153.
35. Kosuga M, Takahashi S, Sasaki K, et al. Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: involvement of cross-correction in wide-spread distribution of the gene products and long-term effects of CTLA-4Ig coexpression. Mol Ther 2000; 1: 406-413.
36. Wen SF, Chen Z, Nery J, Faha B . Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits. Exp Eye Res 2003; 77: 355-365. (Pubitemid 36952374)
37. Hiltunen MO, Turunen MP, Turunen AM, et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000; 14: 2230-2236.
38. Cichon G, Schmidt HH, Benhidjeb T, et al. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J Gene Med 1999; 1: 360-371. (Pubitemid 129631136)
39. Tolcher AW, Hao D, de Bono J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 2006; 24: 2052-2058. (Pubitemid 46622114)
40. Wang L, Hernandez-Alcoceba R, Shankar V, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 2004; 126: 278-289. (Pubitemid 38040742)
41. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther 2005; 16: 664-677. (Pubitemid 40864267)
42. Koski A, Rajecki M, Guse K, et al. Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J Gene Med 2009; 11: 966-977.
43. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8: 1347-1353. (Pubitemid 32834304)
44. Wood M, Perrotte P, Onishi E, et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999; 6: 367-372. (Pubitemid 129667809)
45. Hackett NR, El Sawy T, Lee LY, et al. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol Ther 2000; 2: 649-656.
46. Turunen MP, Puhakka HL, Koponen JK, et al. Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 2002; 6: 306-312.
47. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81: 2605-2609.
48. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14: 227-241. (Pubitemid 36423442)
49. Tian G, Liu J, Zhou JS, Chen W . Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 2009; 20: 389-395.
50. van Etten B, Eggermont AM, van Tiel ST, Ambagtsheer GdWJH, ten Hagen TL. Gene therapy in in vivo isolated perfusion models. Curr Gene Ther 2005; 5: 195-202.
51. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-1297. (Pubitemid 34260418)
52. Matyas L, Schulte KL, Dormandy JA, et al. Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Hum Gene Ther 2005; 16: 1202-1211. (Pubitemid 41443712)
53. Varenne O, Sinnaeve P, Gillijns H, et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum Gene Ther 2000; 11: 1329-1339. (Pubitemid 30395988)
54. Bellon G, Michel-Calemard L, Thouvenot D, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997; 8: 15-25. (Pubitemid 27075339)
55. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333: 823-831.
56. Zuckerman JB, Robinson CB, McCoy KS, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999; 10: 2973-2985.
57. Keedy V, Wang W, Schiller J, et al. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bro chioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 2008; 26: 4166-4171.
58. Worgall S, Leopold PL, Wolff G, Ferris B, Van Roijen N, Crystal RG. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997; 8: 1675-1684. (Pubitemid 28031586)
59. Wolf JK, Bodurka DC, Gano JB, et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 2004; 94: 442-448.
60. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9 : 553-566. (Pubitemid 34734419)
61. Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000; 7: 1511-1518. (Pubitemid 32098762)
62. Wang Y, Yang Z, Liu S, et al. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer 2005; 92: 1414-1420. (Pubitemid 40705008)
63. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609-622. (Pubitemid 30078542)
64. Griscelli F, Opolon P, Saulnier P, et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 2003; 10: 386-395. (Pubitemid 36372446)
65. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 1689-1699. (Pubitemid 46622140)
66. Tursz T, Cesne AL, Baldeyrou P, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996; 88: 1857-1863. (Pubitemid 26425062)
67. Stewart AK, Lassam NJ, Quirt IC, et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 1999; 6: 350-363.
68. Tong AW, Nemunaitis J, Su D, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005; 11: 160-172. (Pubitemid 40012010)
69. Palmer DH, Mautner V, Mirza D, et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22: 1546-1552. (Pubitemid 41079791)
70. Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005; 11: 149-159. (Pubitemid 40012009)
71. Mundt AJ, Vijayakumar S, Nemunaitis J, et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004; 10: 5747-5753. (Pubitemid 39180951)
72. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-2232. (Pubitemid 28265061)
73. Wu J, Xiao X, Jia H, et al. Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. BMC Cancer 2009; 9: 55-61.
74. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1: 195-203.
75. Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65: 279-289. (Pubitemid 37526820)
76. Trudel S, Trachtenberg J, Toi A, et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 2003; 10: 755-763. (Pubitemid 37243796)
77. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res 2003; 63: 7497-7506. (Pubitemid 37413494)
78. Barton KN, Tyson D, Stricker H, et al. GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther 2003; 8: 508-518. (Pubitemid 37161473)
79. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999; 10: 1239-1249.
80. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003; 7: 851-858. (Pubitemid 36790262)
81. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508-2518.
82. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197-2205.
83. Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10: 967-972. (Pubitemid 39419922)
84. Gu DL, Nguyen T, Gonzalez AM, et al. Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use. Mol Ther 2004; 9: 699-711. (Pubitemid 38660423)
85. Veneziale RW, Bral CM, Sinha DP, et al. SCH 412499: biodistribution and safety of an adenovirus containing P21(WAF-1/CIP-1) following subconjunctival injection in Cynomolgus monkeys. Cutan Ocul Toxicol 2007; 26: 83-105.
86. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vectordelivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17: 167-176.
87. Zheng C, Voutetakis A, Kok MR, et al. Toxicity and biodistribution of a first-generation recombinant adenoviral vector, in the presence of hydroxychloroquine, following retroductal delivery to a single rat submandibular gland. Oral Dis 2006; 12: 137-144.
88. Zheng C, Goldsmith CM, Mineshiba F, et al. Toxicity and biodistribution of a first-generation recombinant adenoviral vector, encoding aquaporin-1, after retroductal delivery to a single rat submandibular gland. Hum Gene Ther 2006; 17: 1122-1133. (Pubitemid 44749713)
89. Chang PC, Cirelli JA, Jin Q, et al. Adenovirus encoding human platelet-derived growth factor-B delivered to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use. Hum Gen Ther 2009; 20: 486-496.
90. Senoo M, Matsubara Y, Fujii K, et al. Adenovirus-mediated in utero gene transfer in mice and guinea pigs: tissue distribution of recombinant adenovirus determined by quantitative TaqManpolymerase chain reaction assay. Mol Genet Metab 2000; 69: 269-276. (Pubitemid 30333661)
91. Wang AY, Peng PD, Ehrhardt A, Storm TA, Kay MA. Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum Gene Ther 2004; 15: 405-413. (Pubitemid 38469782)
92. Lenaerts L, McVey JH, Baker AH, et al. Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. J Gene Med 2009; 11: 119-127.
93. Liu J, Saghizadeh M, Tuli SS, et al. Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapy. Mol Vis 2008; 14: 2087-2096.
94. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-1583. (Pubitemid 29465516)
95. Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Hum Gene Ther 2002; 13: 579-604. (Pubitemid 34264310)
96. Tang Y, Han T, Everts M, et al. Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Gene Ther 2007; 14: 523-532. (Pubitemid 46390925)